TMX Newsfile | May 4, 2026 5:22 PM EDT Toronto, Ontario–(Newsfile Corp. – May 4, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company’s audited consolidated financial statements for the twelve-month period ended December 31st, 2025 (“Financial Statements“). Theralase® will be hosting a conference call on May 12th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal year ending December 31st, 2025. To ensure Theralase® has time to address questions during the call, please e-mail them in advance to mperraton@theralase.com. Zoom Meeting Link:  https://us02web.zoom.us/j/82405815948      Conference Call in:  1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom.   An archived version will be available on the website following … Read More

TMX Newsfile | Apr 13, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – April 13, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of Muscle Invasive Bladder Cancer (“MIBC“). Kaplan–Meier survival analysis from the orthotopic MIBC animal study demonstrated that 100% of the animals treated with X-Ray-activated Rutherrin® exhibited a complete response and remained cancer-free at the end of the study; whereas, animals assigned to the radiation only or untreated control group did not respond as well. (See Figure 1). Figure 1: Kaplan-Meier Survival Curve Demonstrating Complete Response of Animals Treated with X-Ray-activated Rutherrin® in MIBC Animal Model To view an enhanced version of … Read More

TMX Newsfile | Apr 10, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – April 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering (“Offering“) of units (“Units“) and a Line Of Credit (“LOC“). On closing of the Offering, the Corporation issued an aggregate of 6,404,700 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,665,222. Each Unit consisted of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.36 per share for a period of 5 years following … Read More

TMX Newsfile | Mar 17, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 17, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company, dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce the discovery of an additional Mechanism Of Action (“MOA“) as to how Ruvidar® is so effective in the inactivation of the Herpes Simplex Virus (“HSV-1“). Theralase® previously reported that Ruvidar® (TLD-1433) was effective in the inactivation of HSV-1 and was superior to the standard of care treatment Acyclovir. See Figure 1.1,2,3 (April 10, 2025 – “Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments” and September 24, 2025 – “Independent Research Demonstrates Ruvidar® Effective in the Destruction of Herpes Simplex Virus“) Figure 1: Anti-viral effect of Ruvidar® versus Acyclovir in HSV-1 (24 hours … Read More

TMX Newsfile | Mar 10, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering (“Offering“) of units (“Units“). On closing, the Corporation issued an aggregate of 4,230,770 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,100,000. Each Unit consisted of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.36 per share for a period of 5 years following the date of closing. The Company plans to … Read More

TMX Newsfile | Mar 9, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 9, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in the destruction of Muscle Invasive Bladder Cancer (“MIBC“). In the MIBC preclinical models conducted by the Theralase® research team, Rutherrin® demonstrated an ability to significantly enhance the efficacy of radiation therapy in the destruction of MIBC, supporting its potential as an effective drug for this devastating condition. Approximately 25% of the 83,000+ new bladder cancer cases diagnosed annually in the United States and 13,300+ cases in Canada are MIBC. MIBC carries a significant risk of death that has not changed in decades.1,2 The standard … Read More

TMX Newsfile | Mar 2, 2026 7:00 AM EST Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with Interferon Toronto, Ontario–(Newsfile Corp. – March 2, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that recent in vitro data demonstrates an enhanced bladder cancer cell kill, when light-activated Ruvidar® is combined with recombinant human interferon alpha-2b (“rhIFNα2b” or “interferon“). In preclinical research, T24 human bladder cancer cells were treated with two concentrations of light-activated Ruvidar® or left untreated. After activation with green light, cells were exposed to increasing doses of rhIFNα2b. The effectiveness of the treatment was assessed by how many cancer cells were killed 48 hours post-treatment. Figure 1: T24 … Read More

TMX Newsfile | Feb 20, 2026 7:00 AM EST This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past. Toronto, Ontario–(Newsfile Corp. – February 20, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the 2026 European Association of Urology Congress (“EAU26“). The EAU has accepted Theralase®’s abstract titled, “Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ” for presentation at EAU26 to be held in London, United Kingdom, from March 13th to 16th, 2026. The interim clinical data from Theralase®’s international, multicenter Phase II Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder … Read More

TMX Newsfile | Feb 10, 2026 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – February 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the American Urological Association (“AUA“) Annual Meeting. The program committee of the AUA has accepted Theralase®’s abstract titled, “Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ” for an interactive poster presentation at the 2026 AUA Annual Meeting to be held in Washington, DC, from May 15th to 18th, 2026. The interim clinical data from Theralase®’s international, multicenter Phase II Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) study (“Study II“) will … Read More

Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response Toronto, Ontario – February 4, 2026 Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to provide an update on the Phase II clinical study for bladder cancer. To date, 90 patients have been enrolled and treated with the Theralase® Study Procedure, achieving the patient enrollment specified by the statistical analysis plan. 78 patients have completed the clinical study and were evaluated at all scheduled assessment visits or were prematurely removed by the principal investigator due to lack of response. There are 12 patients pending study completion. Primary Endpoint Performance (CR at any Point in Time) # % Confidence Interval … Read More